Does MOTS-c have a known receptor?

No. Without one, effects can be measured but are difficult to attribute to a specific pathway.

Why does the site of translation matter?

Mitochondrial and nuclear genetic codes differ, so the same reading frame yields different peptides depending on which ribosomes read it.

Is there human interventional data?

No established programme. Human observations are correlational — measured levels related to exercise or metabolic state.

MOTS-c (Mitochondrial Peptide)

The Structural Reasons the Evidence Is Thin

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

MOTS-c has no identified receptor, an unresolved question about where it is translated, a mechanism described as indirect, and two oxidation-prone residues. Each of these is a structural obstacle to producing the kind of evidence the field would want.

Key facts

Receptor: None identified
Site of translation: Not settled
Mechanism: Indirect, via folate cycle and AMPK
Chemistry: Two oxidation-prone methionines
Human data: Correlational
Interventional trials: None established

No receptor means no standard toolkit

A defined receptor gives a field its instruments: binding assays, dose-response curves, selective antagonists to prove that an observed effect runs through the proposed pathway. Without one, an effect can be measured but not readily attributed. This is the same gap that has kept DSIP unresolved for nearly fifty years, and it is the single most limiting feature here.

The translation question is upstream of everything

Mitochondrial and nuclear genetic codes differ, so the same reading frame produces different peptides depending on which ribosomes read it. For a mitochondrially encoded peptide, that is not a detail — it determines what the endogenous molecule actually is. A synthetic peptide made to one interpretation may not match what a cell produces.

Research material referenced

MOTS-C 10mg — third-party HPLC tested

View — £24.99

An indirect mechanism is harder to test

The described route runs through the folate cycle to an intermediate that activates AMPK, rather than through direct receptor engagement. Indirect mechanisms are scientifically interesting and experimentally awkward, because every step between the compound and the readout is somewhere the causal chain can break or be confounded.

The chemistry adds a practical layer

Two methionines at 12.5% of the sequence oxidise readily, producing +16 and +32 Da species. A preparation that has partly oxidised is not the compound specified, and if oxidation state is not checked it becomes an uncontrolled variable across experiments. That is a mundane obstacle and it is a real one.

Why the human evidence stays correlational

Measuring circulating levels and relating them to exercise or metabolic state produces associations. Turning those into causal claims requires intervention, and no established human interventional programme exists. The ceiling on the human data is a consequence of what has been done, not of what could be.

What would move it forward

An identified receptor or binding partner. Resolution of where translation occurs. Controlled human intervention. None of these is impossible and none has happened, and being clear about that is more useful than the promising framing that surrounds this compound. Material supplied here is for laboratory research only.

Extended research context

The MOTS-c (Mitochondrial Peptide) deep dive

Deep dive: why a peptide encoded in mitochondrial DNA is unusual

The human mitochondrial genome is 16,569 base pairs encoding 37 genes, and was considered fully characterised by the 1980s: thirteen respiratory-chain proteins, twenty-two transfer RNAs, two ribosomal RNAs. MOTS-c is encoded by a short open reading frame nested inside the 12S rRNA gene — sequence already annotated as doing something else, which is exactly why it went unnoticed. Humanin, found in 2001 inside the 16S rRNA gene, established that the genome held more than its annotation suggested; MOTS-c was found in 2015 by looking deliberately. The implication is that the mitochondrion encodes and releases signalling molecules of its own, rather than only executing instructions sent from the nucleus.

Deep dive: AMPK activation without touching AMPK

AMPK is normally activated when AMP and ADP bind its gamma subunit, making it a direct sensor of the AMP-to-ATP ratio. MOTS-c does not raise that ratio and does not bind the kinase. It inhibits the folate cycle, the one-carbon pathway feeding de novo purine biosynthesis, and the intermediate AICAR accumulates as a result. AICAR is an AMP mimetic — phosphorylated to ZMP, it binds the same regulatory site AMP occupies. So the peptide reaches a cytosolic energy sensor through one-carbon metabolism and a diffusible small molecule, which is a materially different architecture from a receptor-ligand interaction, and different again from metformin's inhibition of complex I.

Deep dive: reading a preclinical literature honestly

Roughly 250 indexed papers exist, and the overwhelming majority are cell and rodent studies. Where humans appear, the work is generally observational: measuring circulating concentrations and correlating them with age, fitness or metabolic state. The 2021 Nature Communications paper is the clearest example of the structure — the human arm measured MOTS-c before and after exercise, finding roughly a 12-fold rise in skeletal muscle against 1.6-fold in circulation, while the interventional work was done in mice. Two inferences the secondary literature routinely makes and the primary literature does not support: that a correlation between low concentrations and poor metabolic health establishes direction, and that a molecule which rises during exercise would reproduce exercise if administered.

Research applications

▸Study of mitochondrial-derived peptides and retrograde signalling
▸AMPK pathway research through non-canonical activation
▸One-carbon and folate-cycle metabolism models
▸Exercise physiology and mitochondrial bioenergetics research
▸Ageing biology and mitochondrial genome expression studies

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the primary degradation route (+16 Da per residue)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check mass spectrometry for +16 and +32 satellites before relying on a batch

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading exercise induction as proof that administration mimics exercise

Fix: The papers report that exercise raises MOTS-c. The reverse inference is not supported and is not claimed.

✗ Treating human observational data as interventional evidence

Fix: Human work measures endogenous concentrations; administration studies were conducted in mice.

✗ Assuming MOTS-c has a cell-surface receptor like humanin

Fix: No receptor is established. Its characterised activity is intracellular.

✗ Storing reconstituted material as though it were as stable as the powder

Fix: Solution-phase material is subject to hydrolysis and oxidation; the lyophilised form is far more stable.

✗ Overlooking WADA status in athlete-adjacent research

Fix: MOTS-c is on the prohibited list; this is relevant to any research context involving competitors.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does MOTS-c have a known receptor?: No. Without one, effects can be measured but are difficult to attribute to a specific pathway.
Why does the site of translation matter?: Mitochondrial and nuclear genetic codes differ, so the same reading frame yields different peptides depending on which ribosomes read it.
Is there human interventional data?: No established programme. Human observations are correlational — measured levels related to exercise or metabolic state.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MOTS-c (Mitochondrial Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum